ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...

Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...

ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...

Leuprolide acetate 7.5mg; depot susp for IM inj; preservative-free. Give as single IM inj into gluteal area, anterior thigh or deltoid; rotate inj sites. 7.5mg once a month (4 weeks). Initial ...

Leuprolide acetate 45mg; depot susp for IM inj; preservative-free. Give as single IM inj into gluteal area, anterior thigh or deltoid; rotate inj sites. 45mg once every 6 months (24 weeks). Do not ...

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer. Abbott announced Monday the approval of a 45-mg, six-month ...

Cipla Limited and its wholly owned subsidiary Cipla USA Inc., has announced the launch of leuprolide acetate injection depot 22.5mg. The product was approved by the United States Food and Drug ...

ABBOTT PARK, Ill. Abbott is hoping that the Food and Drug Administration will approve one of its drugs as a treatment for advanced prostate cancer. The Chicago-based drug maker announced Thursday that ...

Paul Hinds, a cybersecurity expert who likes yoga and bicycling, was diagnosed with prostate cancer about five years ago. He tried multiple treatments before turning to intramuscular shots of Lupron ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cvwck3/lupron_depot) has announced the addition of GlobalData's new report ...